Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

SAGE THERAPEUTICS, INC.

(SAGE)
  Report
Delayed Nasdaq  -  01:00 2022-11-25 pm EST
37.79 USD   +0.91%
11/23Sage Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference
BU
11/22Sage Therapeutics and Biogen to Host Investor Webcast on December 6, 2022 to Discuss Potential Commercialization Plans for Zuranolone
BU
11/21Morgan Stanley Adjusts Price Target on Sage Therapeutics to $50 From $53, Maintains Equal-Weight Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Days
:
Hours
:
Minutes
:
Seconds

Sage Therapeutics, Inc. announced that it has received $649.986998 million in funding from Biogen MA Inc.

12/31/2020 EST

On December 31, 2020, Sage Therapeutics, Inc. (NasdaqGM:SAGE) closed the transaction. The company raised $649,986,998 pursuant to Regulation D.


ę S&P Capital IQ 2020
All news about SAGE THERAPEUTICS, INC.
11/23Sage Therapeutics to Present at the Piper Sandler 34th Annual Healthcare Conference
BU
11/22Sage Therapeutics and Biogen to Host Investor Webcast on December 6, 2022 to Discuss Po..
BU
11/21Morgan Stanley Adjusts Price Target on Sage Therapeutics to $50 From $53, Maintains Equ..
MT
11/15Insider Buy: Sage Therapeutics
MT
11/11Guggenheim Adjusts Price Target on Sage Therapeutics to $48 From $55, Maintains Buy Rat..
MT
11/09BMO Capital Adjusts Price Target on Sage Therapeutics to $40 From $43, Maintains Market..
MT
11/09HC Wainwright Adjusts Price Target on Sage Therapeutics to $50 From $55, Maintains Neut..
MT
11/09Sage Therapeutics to Present at the Stifel 2022 Healthcare Conference
BU
11/08Wedbush Adjusts Sage Therapeutics Price Target to $48 From $52, Maintains Outperform Ra..
MT
11/08ETF Preview: ETFs, Stock Futures Edge Up Pre-Bell After Small Business Optim..
MT
More news
Analyst Recommendations on SAGE THERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 6,80 M - -
Net income 2022 -529 M - -
Net cash 2022 1 304 M - -
P/E ratio 2022 -4,26x
Yield 2022 -
Capitalization 2 248 M 2 248 M -
EV / Sales 2022 139x
EV / Sales 2023 12,2x
Nbr of Employees 471
Free-Float 87,5%
Chart SAGE THERAPEUTICS, INC.
Duration : Period :
Sage Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SAGE THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 37,79 $
Average target price 55,41 $
Spread / Average Target 46,6%
EPS Revisions
Managers and Directors
Barry E. Greene President, Chief Executive Officer & Director
Kimi E. Iguchi Chief Financial Officer
Kevin Paul Starr Chairman
Albert J. Robichaud Chief Scientific Officer
Amy Schacterle Senior VP-Research & Development Strategy
Sector and Competitors
1st jan.Capi. (M$)
SAGE THERAPEUTICS, INC.-11.17%2 248
VERTEX PHARMACEUTICALS42.52%80 339
REGENERON PHARMACEUTICALS, INC.16.58%78 631
BIONTECH SE-39.93%37 632
WUXI APPTEC CO., LTD.-30.90%33 214
GENMAB A/S20.53%28 930